CHEERS-AI Economic Evaluation

By João L. Carapinha

November 5, 2024

CHEERS-AI economic evaluation

NICE (National Institute for Health and Care Excellence) introduces CHEERS-AI! It’s a new reporting standard optimized for health economic evaluations of AI technologies in healthcare. The EU funded CHEERS-AI as part of the Next Generation Health Technology Assessment (HTx) project. Its primary aim is to enhance the transparency and quality of cost-effectiveness studies specifically tailored for AI-enabled healthcare interventions.

Purpose and Background

CHEERS-AI seeks to systematically address the challenges facing health economic evaluations of AI interventions. A systematic review has identified several issues, including poor quality input data, author conflicts of interest, lack of transparent reporting, and vague information regarding AI functionality.

Solution: CHEERS-AI economic evaluation

Building on the established CHEERS 2022 standards, CHEERS-AI incorporates the original 28 standards while adding 8 new details for AI-related nuances and 10 AI-specific standards. The extra standards tackle key aspects such as user autonomy, continuous AI learning, and the methodology behind developing the AI component.

Objectives

The primary goal of CHEERS-AI is to ensure transparent and reproducible reporting of AI-specific details in health economic evaluations. This standard will aid healthcare decision-makers in understanding the value of AI-enabled treatments, ultimately facilitating faster access to promising AI technologies for patients.

Endorsement and Integration

ISPOR endorsed CHEERS-AI and is now included in the EQUATOR Network checklist of reporting guidelines. This endorsement ensures integration into best practices for health economic evaluation reporting.

Impact

Refining the quality and transparency of health economic evaluations involving AI technologies is an important objective. In doing so, CHEERS-AI aims to elevate the standards of economic evaluation reporting. This improvement is vital for reimbursement decisions and the broader adoption of AI in healthcare.

In summary, CHEERS-AI represents an advancement in standardizing and enhancing health economic evaluations of AI technologies, thereby supporting improved decision-making in healthcare.

Reference url

Recent Posts

cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...